Drugs / AllerT
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01719133 | Feb → Mar 2008 | allergic rhinitis | Anergis | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01728519 | Aug 2008 → Mar 2009 | allergic rhinitis | Anergis | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02943720 | Sep 2016 → Jul 2017 | allergic rhinitis | Anergis | Completed | No outcome recorded |
| Phase 2 | NCT01720251 | Oct 2012 → Sep 2013 | allergic rhinitis | Anergis | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02271009 Comparator | Oct 2014 → May 2015 | allergic disease | Anergis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AllerT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01728519 ↗ |
| Known as | mix of AllerT1-T2-T3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01719133 ↗ |
| Modality | Peptide | “mix of peptides T1, T2 and T3” NCT01719133 ↗ |
| Route | Other | “all by skin tests” NCT01719133 ↗ |